Covered recipient · General Payments record
KAMI J MADDOCKS
Allopathic & Osteopathic Physicians Internal Medicine Hematology
General Payments · PY2018–2024
$211,890.94
- Reported across 163 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $49,398.50 | 15 |
| Travel and Lodging | $6,334.94 | 5 |
| Food and Beverage | $384.17 | 4 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $18,557.10 | 3 |
| ABBVIE INC. | $7,014.76 | 4 |
| Genentech USA, Inc. | $6,922.59 | 4 |
| Genmab U.S., Inc. | $6,417.16 | 6 |
| Acerta Pharma LLC | $5,480.00 | 2 |
| E.R. Squibb & Sons, L.L.C. | $4,941.00 | 2 |
| Eli Lilly and Company | $3,600.00 | 1 |
| Merck Sharp & Dohme Corporation | $3,050.00 | 1 |
| AstraZeneca UK Limited | $135.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (24)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $2,900.00 | 09/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104921840 | CMS |
| ABBVIE INC. | $127.26 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104921842 | CMS |
| ABBVIE INC. | $2,537.50 | 12/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104921844 | CMS |
| ABBVIE INC. | $1,450.00 | 12/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104921846 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,055.00 | 08/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105816595 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,425.00 | 10/23/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105745686 | CMS |
| AstraZeneca UK Limited | $135.00 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1094033512 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,076.00 | 08/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101312027 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,865.00 | 10/15/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101312035 | CMS |
| Eli Lilly and Company | $3,600.00 | 02/23/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1135118661 | CMS |
| Genentech USA, Inc. | $2,660.00 | 07/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133043984 | CMS |
| Genentech USA, Inc. | $1,900.00 | 09/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133043972 | CMS |
| Genentech USA, Inc. | $82.59 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133043976 | CMS |
| Genentech USA, Inc. | $2,280.00 | 12/05/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133043980 | CMS |
| Genmab U.S., Inc. | $47.99 | 06/11/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126828416 | CMS |
| Genmab U.S., Inc. | $408.95 | 06/11/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126828418 | CMS |
| Genmab U.S., Inc. | $365.70 | 06/11/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126828420 | CMS |
| Genmab U.S., Inc. | $355.20 | 06/11/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126828424 | CMS |
| Genmab U.S., Inc. | $5,200.00 | 07/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1126828422 | CMS |
| Genmab U.S., Inc. | $39.32 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126828426 | CMS |
| Lilly USA, LLC | $5,157.10 | 09/20/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1135089211 | CMS |
| Lilly USA, LLC | $5,600.00 | 09/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1135075931 | CMS |
| Lilly USA, LLC | $7,800.00 | 09/27/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1135118663 | CMS |
| Merck Sharp & Dohme LLC | $3,050.00 | 10/28/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141793174 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.